MiMedx Group Full Year 2022 Earnings: In Line With Expectations
MiMedx Group (NASDAQ:MDXG) Full Year 2022 Results
Key Financial Results
Revenue: US$267.8m (up 3.6% from FY 2021).
Net loss: US$36.8m (loss widened by 124% from FY 2021).
US$0.33 loss per share (further deteriorated from US$0.15 loss in FY 2021).
MDXG Post-Clinical Trial Products
Launched (during full year): 2.
All figures shown in the chart above are for the trailing 12 month (TTM) period
MiMedx Group Meets Expectations
Revenue was in line with analyst estimates. Earnings per share (EPS) was also in line with analyst expectations.
Looking ahead, revenue is forecast to grow 12% p.a. on average during the next 3 years, compared to a 14% growth forecast for the Biotechs industry in the US.
Performance of the American Biotechs industry.
The company's shares are down 13% from a week ago.
We don't want to rain on the parade too much, but we did also find 2 warning signs for MiMedx Group that you need to be mindful of.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Join A Paid User Research Session
You’ll receive a US$30 Amazon Gift card for 1 hour of your time while helping us build better investing tools for the individual investors like yourself. Sign up here